Novo Nordisk's WEGOVY has secured FDA approval for cardiovascular risk reduction in March 2024, becoming the first obesity medication authorized to reduce cardiovascular death, heart attack, and stroke risks.
Regor Therapeutics' RGT-075, an oral GLP-1 receptor agonist, demonstrated a statistically significant 5% placebo-adjusted weight loss in obese patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.